Shares of Dr Reddy's Laboratories slumped nearly 3% as investors were unimpressed by the company's earnings for the December quarter.The drug maker reported consolidated net profit of Rs290cr, sharply below analysts' estimate of Rs350cr. Continued rise in pricing pressure and lack of new product launches in the US during the quarter weighed on the company's operating margin, which contracted 250bps on year to 21.2%.
CapitalStars Award Winning , SEBI registered , ISO certified investment advisory company. We provide intraday & positional services in Equity , derivative ,commodity & currency. Our research is highly skilled & experienced .
Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
OPTION CALL: BUY RCOM 25 CALL ABOVE 5.70 TARGETS 5.80/ 5.95/ 6.10 STOPLOSS 5.60
ReplyDeleteOPTION UPDATE: RCOM 25 CALL FINAL TARGETS (6.10) HAS ACHIEVED BOOK RS 11200/- PROFIT PER LOT CMP 6.20
Join for INTRADAY CALLS: High Light Research